PL1706121T3 - Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (HSEP) do zapobiegania i leczenia zaburzeń neurodegeneracyjnych - Google Patents

Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (HSEP) do zapobiegania i leczenia zaburzeń neurodegeneracyjnych

Info

Publication number: PL1706121T3
Authority: PL; Poland
Prior art keywords: endopeptidase; hsep; nep; prophylaxis; treatment
Prior art date: 2004-01-12

Application number

PL05701469T

Other languages

English (en)

Inventor

Michael Weske

Lechoslaw A Turski

Hrissanthi Ikonomidou

Dieter Ziegler

Original Assignee

Turski Lechoslaw

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-01-12

Filing date

2005-01-10

Publication date

2009-02-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34796705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1706121(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-01-10 Application filed by Turski Lechoslaw filed Critical Turski Lechoslaw

2009-02-27 Publication of PL1706121T3 publication Critical patent/PL1706121T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Psychology (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Enzymes And Modification Thereof (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

PL05701469T 2004-01-12 2005-01-10 Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (HSEP) do zapobiegania i leczenia zaburzeń neurodegeneracyjnych PL1706121T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US53553804P	2004-01-12	2004-01-12
EP04100067		2004-01-12
EP05701469A EP1706121B1 (en)	2004-01-12	2005-01-10	Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors for prophylaxis and treatment of neurodegenerative disorders
PCT/EP2005/050075 WO2005067937A1 (en)	2004-01-12	2005-01-10	Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors for prophylaxis and treatment of neurodegenerative disorders

Publications (1)

Publication Number	Publication Date
PL1706121T3 true PL1706121T3 (pl)	2009-02-27

Family

ID=34796705

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL05701469T PL1706121T3 (pl)	2004-01-12	2005-01-10	Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (HSEP) do zapobiegania i leczenia zaburzeń neurodegeneracyjnych

Country Status (22)

Country	Link
EP (1)	EP1706121B1 (pl)
JP (1)	JP4951350B2 (pl)
KR (1)	KR101219580B1 (pl)
CN (1)	CN101076339B (pl)
AT (1)	ATE406899T1 (pl)
AU (1)	AU2005205067B2 (pl)
BR (1)	BRPI0506750A (pl)
CA (1)	CA2551789C (pl)
CY (1)	CY1108588T1 (pl)
DE (1)	DE602005009487D1 (pl)
DK (1)	DK1706121T3 (pl)
ES (1)	ES2313279T3 (pl)
HR (1)	HRP20080611T3 (pl)
IL (1)	IL176456A (pl)
NO (1)	NO20063623L (pl)
PL (1)	PL1706121T3 (pl)
PT (1)	PT1706121E (pl)
RU (1)	RU2362563C2 (pl)
SI (1)	SI1706121T1 (pl)
UA (1)	UA82008C2 (pl)
WO (1)	WO2005067937A1 (pl)
ZA (1)	ZA200605549B (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2010207597A1 (en) *	2009-01-24	2011-08-18	Phytopharm Plc	Treatment of neurotrophic factor mediated disorders
AR079059A1 (es)	2009-12-07	2011-12-21	Abbott Healthcare Products Bv	Acido ((3s)-3-(((1-(((2r)-2-carboxi-4-(1-naftil) butil) ciclopentil)-carbonil) amino )-2-oxo-2,3,4,5-tetrahidro-1h-1-benzazepin-1-il) acetico cristalino, su preparacion y uso
CN106065006B (zh) *	2015-04-22	2020-06-05	深圳信立泰药业股份有限公司	一种中性内肽酶抑制剂盐晶型及其制备方法
PL424452A1 (pl)	2018-01-31	2019-08-12	Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością	Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu
PL424453A1 (pl) *	2018-01-31	2019-08-12	Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością	Sposoby zmniejszania szkodliwego działania niedoboru perfuzji narządów miąższowych przez inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP)
CN110590695B (zh) *	2019-10-22	2023-03-21	南华大学	苯并氮杂环类化合物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19510566A1 (de) *	1995-03-23	1996-09-26	Kali Chemie Pharma Gmbh	Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19750002A1 (de) *	1997-11-12	1999-05-20	Solvay Pharm Gmbh	Phosphonsäure-substituierte Benzazepinon-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
CN1297453A (zh) *	1998-04-23	2001-05-30	诺瓦提斯公司	硫醇类内皮缩血管肽转化酶抑制剂
US20020013307A1 (en) *	2000-05-23	2002-01-31	Pablo Lapuerta	Use of vasopeptidase inhibitors to treat or slow the progression of cognitive dysfunction and to treat and/or prevent dementia
US6505135B2 (en) *	2001-03-13	2003-01-07	Micro Motion, Inc.	Initialization algorithm for drive control in a coriolis flowmeter
HUP0400988A3 (en) *	2001-05-18	2006-07-28	Solvay Pharm Gmbh	Use of compounds with combined nep/mp-inhibitory activity in the preparation of medicaments
CL2004000545A1 (es) *	2003-03-18	2005-01-28	Pharmacia Corp Sa Organizada B	Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul

2005
- 2005-01-10 DK DK05701469T patent/DK1706121T3/da active
- 2005-01-10 JP JP2006548311A patent/JP4951350B2/ja active Active
- 2005-01-10 EP EP05701469A patent/EP1706121B1/en active Active
- 2005-01-10 BR BRPI0506750-2A patent/BRPI0506750A/pt not_active Application Discontinuation
- 2005-01-10 CN CN2005800022847A patent/CN101076339B/zh active Active
- 2005-01-10 PT PT05701469T patent/PT1706121E/pt unknown
- 2005-01-10 DE DE602005009487T patent/DE602005009487D1/de active Active
- 2005-01-10 AU AU2005205067A patent/AU2005205067B2/en not_active Ceased
- 2005-01-10 AT AT05701469T patent/ATE406899T1/de active
- 2005-01-10 RU RU2006129288/15A patent/RU2362563C2/ru active
- 2005-01-10 WO PCT/EP2005/050075 patent/WO2005067937A1/en active IP Right Grant
- 2005-01-10 ES ES05701469T patent/ES2313279T3/es active Active
- 2005-01-10 CA CA2551789A patent/CA2551789C/en not_active Expired - Fee Related
- 2005-01-10 PL PL05701469T patent/PL1706121T3/pl unknown
- 2005-01-10 SI SI200530457T patent/SI1706121T1/sl unknown
- 2005-10-01 UA UAA200609032A patent/UA82008C2/uk unknown
2006
- 2006-06-21 IL IL176456A patent/IL176456A/en active IP Right Grant
- 2006-07-05 ZA ZA200605549A patent/ZA200605549B/xx unknown
- 2006-08-10 NO NO20063623A patent/NO20063623L/no not_active Application Discontinuation
- 2006-08-11 KR KR1020067016297A patent/KR101219580B1/ko active IP Right Grant
2008
- 2008-11-24 CY CY20081101348T patent/CY1108588T1/el unknown
- 2008-11-25 HR HR20080611T patent/HRP20080611T3/xx unknown

Also Published As

Publication number	Publication date
ZA200605549B (en)	2007-12-27
JP4951350B2 (ja)	2012-06-13
AU2005205067B2 (en)	2009-10-22
DK1706121T3 (da)	2009-01-05
BRPI0506750A (pt)	2007-05-22
ATE406899T1 (de)	2008-09-15
SI1706121T1 (sl)	2009-02-28
KR20060123541A (ko)	2006-12-01
RU2362563C2 (ru)	2009-07-27
CN101076339B (zh)	2011-02-09
IL176456A0 (en)	2006-10-05
AU2005205067A1 (en)	2005-07-28
DE602005009487D1 (de)	2008-10-16
RU2006129288A (ru)	2008-02-20
EP1706121A1 (en)	2006-10-04
KR101219580B1 (ko)	2013-01-08
CN101076339A (zh)	2007-11-21
IL176456A (en)	2010-03-28
EP1706121B1 (en)	2008-09-03
ES2313279T3 (es)	2009-03-01
JP2007517834A (ja)	2007-07-05
PT1706121E (pt)	2008-12-04
CA2551789C (en)	2011-05-03
UA82008C2 (uk)	2008-02-25
WO2005067937A1 (en)	2005-07-28
HRP20080611T3 (en)	2008-12-31
CA2551789A1 (en)	2005-07-28
CY1108588T1 (el)	2014-04-09
NO20063623L (no)	2006-10-12

Publication	Publication Date	Title
GEP20125565B (en)	2012-07-10	Lactam compounds and their pharmaceutical use
HRP20041132A2 (en)	2006-07-31	7-aryl-3, 9-diazabicyclo (3.3.1) non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases
UA86614C2 (ru)	2009-05-12	Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
MY144992A (en)	2011-12-15	Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
SG179034A1 (en)	2012-04-27	2 -aminodihydro [1, 3] thiazines as bace 2 inhibitors for the treatment of diabetes
WO2006011050A3 (en)	2006-10-05	Pyridine derivatives
TW200722081A (en)	2007-06-16	New therapeutic combinations for the treatment or prevention of depression
IL176546A0 (en)	2006-10-31	Imidazoline derivatives having cb1-antagonistic activity
TW200514772A (en)	2005-05-01	Novel tetrahydropyridine derivatives
HRP20080611T3 (en)	2008-12-31	Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors for prophylaxis and treatment of neurodegenerative disorders
PL1682528T3 (pl)	2008-01-31	Pochodne benzo[b][1,4]dioksepiny
WO2005040171A8 (en)	2006-08-03	Pyrazolo and imidazo-pyrimidine derivatives
TW200637861A (en)	2006-11-01	Novel diazabicyclononene derivative
TW200621716A (en)	2006-07-01	Novel compounds
GB0420831D0 (en)	2004-10-20	Novel compounds
MXPA05011498A (es)	2005-12-15	Derivados de 9-azabiciclo[3.3.1]non-6-eno con un heteroatomo en la posicion 3 como inhibidores de renina.
WO2005030209A8 (en)	2006-05-11	Pyridine derivatives and use thereof as urotensin ii antagonists
MXPA05011496A (es)	2005-12-15	Derivados de azabiciclononeno.
TW200611701A (en)	2006-04-16	Novel compounds
IL187001A0 (en)	2008-02-09	Preparation of (s)-4-fluromethyl-dihydro-furan -2-one
WO2007111983A3 (en)	2008-05-29	New therapeutic combinations for the treatment or prevention of psychotic disorders
TW200621773A (en)	2006-07-01	Bicyclononene derivatives
TW200621774A (en)	2006-07-01	Bicyclononene derivatives
TW200634014A (en)	2006-10-01	Novel diazabicyclononene derivative
TW200621255A (en)	2006-07-01	Novel compounds